Estimation of withdrawal interval recommendations following administration of fenbendazole medicated feed to ring-necked pheasants ( Phasianus colchicus ).

Autor: Carreño Gútiez M; Department of Medicine and Epidemiology, Center for Animal Disease Modeling and Surveillance (CADMS), School of Veterinary Medicine, University of California, Davis, Davis, CA, United States., Mercer MA; Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States., Martínez-López B; Department of Medicine and Epidemiology, Center for Animal Disease Modeling and Surveillance (CADMS), School of Veterinary Medicine, University of California, Davis, Davis, CA, United States., Griffith RW; Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States., Wetzlich S; Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States., Tell LA; Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
Jazyk: angličtina
Zdroj: Frontiers in veterinary science [Front Vet Sci] 2024 Jul 31; Vol. 11, pp. 1444009. Date of Electronic Publication: 2024 Jul 31 (Print Publication: 2024).
DOI: 10.3389/fvets.2024.1444009
Abstrakt: Introduction: Prescribing fenbendazole medicated feed for pheasants in the USA is considered extra-label drug use under CPG Sec 615.115, and a safe estimated withdrawal interval (WDI) must be applied following administration to this minor food-producing species. This study sought to determine the pharmacokinetic and residue depletion profile for fenbendazole and its major metabolites to estimate a WDI for pheasants following fenbendazole administration as an oral medicated feed.
Method: Pheasants ( n = 32) were administered fenbendazole as an oral medicated feed (100 ppm) for 7 days. Fenbendazole, fenbendazole sulfoxide, and fenbendazole sulfone (FBZ-SO 2 ) in liver and muscle samples were analyzed using HPLC-UV. Tissue WDIs were estimated using FDA, European Medicines Agency (EMA), and half-life multiplication methods for US poultry tolerances, EMA maximum residue limits, and the analytical limit of detection (LOD; 0.004 ppm). Terminal tissue elimination half-lives (T 1/2 ) were estimated by non-compartmental analysis using a naïve pooled data approach.
Results: The tissue T 1/2 was 14.4 h for liver, 13.2 h for thigh muscle, and 14.1 h for pectoral muscle. The maximum estimated withdrawal interval was 153 h (7 days) for FBZ-SO 2 in pectoral muscle using the FDA tolerance method (95% confidence interval for the 99 th percentile of the population), and the LOD as the residue limit.
Discussion: The results from this study support the use of FBZ-SO 2 as the marker residue in the liver of pheasants and the provision of evidence based WDIs following the extra-label administration of fenbendazole medicated feed (100 ppm) for 7 days.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Carreño Gútiez, Mercer, Martínez-López, Griffith, Wetzlich and Tell.)
Databáze: MEDLINE
Externí odkaz: